B-31/N9831 First Interim Joint Analysis NSABP Meeting Baltimore MD 17 September 2005 Edward H. Romond, M.D. Joint Analysis Flow Diagram Trial Number Registered1 ...
H=trastuzumab (4mg/kg loading dose, followed by 2mg/kg) ... Modest level of concordance between local and central laboratories for both IHC and FISH ...
Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831
... be confirmed in the other central lab Central Laboratory HER2 % local false-positive ER % discordant IEO 14.5% of 8,037 12.1% of 9,021 Mayo Clinic 5.8% of ...
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) ... Edith A. Perez, PI. N9831: Intergroup Trial for. Node , HER2 Breast Cancer. Paclitaxel qw x 12 ...
Targeted Adjuvant Systemic Therapy of Breast Cancer. Current & Future Role of Trastuzumab ... or High Risk Node (-) Breast Cancer. NCCTG N9831. May 2005 Update ...
European Cooperative Trial in Operable Breast Cancer(ECTO): Improved freedom ... History of congestive heart failure. Angina pectoris requiring medication ...
Title: Presentaci n de PowerPoint Author: Packard Bell NEC, Inc. Last modified by: Administrador Created Date: 3/19/2001 8:15:16 PM Document presentation format
The incidence of cardiac events reach a plateau at around 1 year ... survival, time to recurrence, and time to ... NOAH study: neoadjuvant Herceptin for LABC ...
ASCO 2005 Adjuvant Breast Cancer Update Lori J. Goldstein, MD Director, Breast Evaluation Center Leader, Breast Cancer Research Program Fox Chase Cancer Center
Current Patterns of Care: Case C a 55 yo with a 2.4-cm, Grade II, ER/PR ... Oak Lawn, Illinois ... 12:05 PM Dr Love: Current patterns of care in the community ...
pathophysiology of HER-2 family of proteins. diagnostic testing ... Paclitaxel for patients who had received adjuvant anthracycline. R. A. N. D. O. M. I. Z. E ...
... it expects an ultimate enrollment of 8,000 patients Co-amplification of c-myc and HER2: benefit of trastuzumab Co-amplification of c-myc and HER2: ...
Discussion Topics HER2 positive disease Growing number of options Angiogenesis Bevacizumab questions answered and rephrased Small molecule success and ...
adjuvant treatment with trastuzumab. AGO Organkommission 'Mamma' as of July 19th, 2005 ... Adjuvant treatment with trastuzumab in primary breast cancer patients ...
DEPARTMENT OF ONCOLOGY AND HEMATOLOGY UNIVERSITY OF MODENA AND REGGIO EMILIA MODENA, ITALY I fattori prognostici del tumore della mammella: possibile un approccio ...
form of adjuvant systemic therapy ... Adjuvant Chemotherapy. Adjuvantonline describes 1st, 2nd and 3rd generation regimens ... Current Adjuvant Trials for HER2 ve pts ...
A meta-analysis of taxanes in adjuvant chemotherapy (ACT) of early breast cancer ... Survival with adjuvant surgical oophorectomy and tamoxifen in premenopausal ...
CONGRESO CHILENO DE CANCEROLOGIA TERAPIAS BIOLOGICAS DIRIGIDAS EN CANCER DE MAMA Dr. Jorge Luis Soriano Garc a Ph.D. Jefe Servicio de Oncolog a Cl nica
in women with HER-2 positive primary breast cancer who have completed adjuvant chemotherapy ... Nodal status, adjuvant CT regimen, hormone receptor status and ...
HER-2 targeting: dalla malattia avanzata alla fase pre-operatoria Marco Venturini Roma, Febbraio 2005 Tailored Treatment of HER2+ MBC Trastuzumab + Taxanes ...
CARCINOMA DELLA MAMMELLA The Aromatase Inhibitor Trials ATAC: Tamoxifen vs Anastrozole vs Combined therapy MA17 : Letrozole vs placebo after 5yr Tamoxifen IES ...
Effets de la radioth rapie post-op ratoire sur les r cidives locor gionales et la survie ... Etabli de fa on empirique, compromis entre efficacit et risque de s quelles ...
Essentials of ALTTO Frances M Palmieri, RN, MSN, OCN, CCRP Nursing Liaison What is ALTTO Worldwide Collaboration Enrollment Update Rationale for Study Design ...
... Treatment in Patients with FISH Positive Advanced or Metastatic Breast Cancer ... Advanced ErbB2 MBC. Prior treatment with trastuzumab allowed but not required ...
Does Omitting IMC Irradiation Reduce Cardiac Exposure For All Breast Cancer ... K. Feng, C.M.D., Andrzej Niemierko, Ph.D., Alphonse G. Taghian, M.D., Ph.D. ...